| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.17 | 0.0001 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.18 | 0.0004 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.26 | 0.0004 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0009 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | 0.23 | 0.001 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | 0.19 | 0.003 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.003 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.1 | 0.004 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.093 | 0.006 |